Table 1: Comparison of clinical data between the PD with the RLS group and the PD with the non-RLS group.

VariablesPD with RLS ()PD with non-RLS ()Test value value

Sex ( (%))0.0220.881a
Male14 (60.87)76 (49.03)
Female9 (39.13)79 (50.97)
Age at presentation (yr, )0.417t0.677b
Age of PD onset (yr, )0.182t0.856b
Duration of PD (yr, M(QR))5.00 (3.00)3.00 (4.00)1452.000.149
Side involved ( (%))0.202a0.653a
Unilateral10 (43.48)76 (49.03)
Bilateral13 (56.52)79 (50.97)
UPDRS III (M(QR))22.00 (13.00)18.00 (13.00)1148.000.006
Hoehn and Yahr stage (M(QR))2.00 (1.00)2.00 (1.50)1465.500.160
PRBD ( (%))0.012c
With PRBD19 (82.61)84 (54.19)
With non-PRBD4 (17.39)71 (45.81)
MMSE score (M(QR))28.00 (4.00)27.00 (3.00)1644.500.545
HAMD score (M(QR))12 (13.00)7.00 (8.00)1023.000.001
Daily LED (mg/day, M(QR))437.50 (350.00)300.00 (287.50)962.00≤0.001

PD = Parkinson’s disease; RLS = restless leg syndrome; UPDRS III = unified Parkinson’s disease rating scale III; PRBD = probable rapid eye movement sleep behavior disorder; MMSE = minimum mental state examination; HAMD = Hamilton depression scale; daily LED = daily levodopa equivalent dose. aFor test, bfor test, cfor Fisher’s exact test, and the rest is test; in PRBD, daily LED, UPDRS III, and HAMD scores.